Loading
A phase 1/2 trial of Erdafitinib, Cetrelimab, Cisplatin and Carboplatin in bladder & urothelial cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer is a phase 1/2 interventional study registered as NCT03473743 by Janssen Research & Development, LLC, with 125 participants enrolled, started 2018-04-05 and due to reach its primary completion in 2022-09-30. Interventions recorded: Erdafitinib, Cetrelimab, Cisplatin and Carboplatin. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
125 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2023-10-25), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Phase 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator Assessmentprimary | Arm A (Phase 2): Erdafitinib 8/9 mg Monotherapy | 43 | 44.2% | - | - | link |
| Arm B (Phase 2): Erdafitinib 8 mg + Cetrelimab 240/480 mg | 44 | 54.5% |
Shares Erdafitinib, Muscle-invasive and advanced bladder cancer, Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
Shares Erdafitinib, Johnson & Johnson, Bladder & urothelial cancer, Small-molecule kinase inhibitors and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Cisplatin, Carboplatin and the tag pipeline.
Shares Cetrelimab, Johnson & Johnson and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Cisplatin, Carboplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Cisplatin, Carboplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Cisplatin, Carboplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Cisplatin, Carboplatin and the tag pipeline.